BIOGEN INC. BIIB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $9.9B | $1.3B | — | $2.1B | $18.3B |
| 2024 | $9.7B | $1.6B | — | $2.7B | $16.7B |
| 2023 | $9.8B | $1.2B | — | $1.3B | $14.8B |
| 2022 | $10.2B | $3.0B | — | $1.1B | $13.4B |
| 2021 | $11.0B | $1.6B | — | $3.4B | $11.0B |
| 2020 | $13.4B | $4.0B | $11.6B | $3.8B | $10.7B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| HAWKINS WILLIAM A | director | 2026-06-09 | Grant | 1,505 | — |
| SHERWIN STEPHEN A | director | 2026-06-09 | Grant | 1,505 | — |
| Rowinsky Eric K | director | 2026-06-09 | Grant | 1,505 | — |
| Mantas Jesus B | director | 2026-06-09 | Grant | 1,505 | — |
| LANGER SUSAN | director | 2026-06-09 | Grant | 1,505 | — |
| Patolawala Monish D | director | 2026-06-09 | Grant | 1,505 | — |
| Pangalos Menelas N | director | 2026-06-09 | Option exercise | 2,370 | — |
| Pangalos Menelas N | director | 2026-06-09 | Grant | 1,505 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0000875045 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.